Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors say
By Nancy Lapid (Reuters) -Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs should be the first medicines doctors…
Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors say
By Nancy Lapid (Reuters) -Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs should be the first medicines doctors…
Ozempic maker urges Ottawa to shut down online drug sales to Americans
OTTAWA — Novo Nordisk, the Danish drug company that makes Ozempic and Wegovy, wants the Canadian government to…
GLP-1 Weight-Loss Pills Could Transform Treatment
A new era of weight-loss treatment could soon trade needles for pills. Drugmakers behind GLP-1 injections like Wegovy…
How the ‘Ozempic effect’ is reshaping the global economy
Michael Siluk/Alamy The new wave of weight-loss drugs has taken the world by storm. From Novo Nordisk’s Ozempic…
How a change in FDA guidance might revolutionise MASH drug development
Transformative new shifts have taken place in the last month in the metabolic dysfunction-associated steatohepatitis (MASH) therapy space,…
Pricing group says weight-loss drugs becoming more cost-effective
By Deena Beasley (Reuters) -An influential drug pricing watchdog on Tuesday said popular GLP-1 weight-loss injections have become…
Here’s Why GreensKeeper Asset Management Added Novo Nordisk (NVO) to Its Portfolio
GreensKeeper Asset Management, an investment management company, released its second-quarter 2025 investor letter. A copy of the letter…
Ozempic reportedly faces $2 billion in lawsuits over severe side effects
Key Takeaways Trending Nearly 2,000 lawsuits allege Ozempic caused health issues including stomach paralysis and vision loss. Celebrity…
Trading in Novo Nordisk shares by board members, executives and associated persons
Novo Nordisk A/S Bagsværd, Denmark, 19 August 2025 — This company announcement discloses the data of the transaction(s) made…
Novo Nordisk lowers cost of Ozempic® to $499 per month for self-paying patients, in support of patient access to authentic, FDA-approved semaglutide medicines
Ozempic® is the GLP-1 with the most FDA-approved uses for patients with type 2 diabetes including, improvement of…
Wegovy® approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis
“Today’s decision by the FDA reflects the continued progress in how we understand and treat patients with MASH,…